What Does 'Best Medical Therapy' Really Mean?

European Journal of Vascular and Endovascular Surgery

Volumn 35, Issue 2, 2008, Pages 139-144

  Sillesen, H ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antiplatelet drugs; Carotid disease; Medical treatment; Prevention clinic; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; CLOPIDOGREL; DIPYRIDAMOLE; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; RAMIPRIL; SIMVASTATIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BRAIN ISCHEMIA; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; DIABETES MELLITUS; ENDARTERECTOMY; HUMAN; LIFESTYLE; LIFESTYLE MODIFICATION; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; RISK REDUCTION; STROKE; SURGEON; THROMBOSIS; TRANSIENT ISCHEMIC ATTACK; UNSPECIFIED SIDE EFFECT;

ANTIHYPERTENSIVE AGENTS; ATTITUDE OF HEALTH PERSONNEL; CAROTID STENOSIS; CLINICAL COMPETENCE; DRUG THERAPY, COMBINATION; ENDARTERECTOMY, CAROTID; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH SERVICES ACCESSIBILITY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOGLYCEMIC AGENTS; LIFE STYLE; PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; RECURRENCE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC; TREATMENT OUTCOME;

EID: 38849137342     PISSN: 10785884     EISSN: 15322165     Source Type: Journal    
DOI: 10.1016/j.ejvs.2007.10.003     Document Type: Review

References (27)

1. European Carotid Surgery Trialist's Collaborative Group. MRC European carotid surgery trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. Lancet 337 (1991) 1235-1243
2. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med 325 (1991) 445-453
3. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid stenosis. JAMA 273 (1995) 1421-1428
4. MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group. Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial. Lancet 363 (2004) 1491-1502
5. Rothwell P.M., Eliasziw M., Gutnikov S.A., Warlow C.P., and Barnett H.J. Carotid Endarterectomy Trialists Collaboration: Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgery. Lancet 363 (2004) 915-924
6. Rothwell P.M., Giles M.F., Chandratheva A., Marquardt L., Geraghty O., Redgrave J.N.E., et al. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet 6 (2007) 953-960
7. Hennerici M., Huelsboemer H.B., Hefter H., Lammerts D., and Rautenberg W. Natural history of asymptomatic extracranial disease. Results of a long-term prospective study. Brain 110 (1987) 777-791
8. Sillesen H., Amarenco P., Szarek M., Callahan A., Goldstein L., Hennerici M., et al. on behalf of the SPARCL Investigators. Atorvastatin treatment in patients with carotid stenosis is associated with a marked reduction in the risk stroke, cardiac events and endarterectomy. A substudy of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Trial. Stroke 38 (2007) 457
9. Antithrombotic Trialists Collaboration. Collaborative meta-analysis of randomised trials of anti-platelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324 (2002) 71-86
10. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 (1996) 1329-1339
11. Diener H.C., Cunha L., Forbes C., Sivenius J., Smets P., and Lowenthal A. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 143 1-2 (1996 Nov) 1-13
12. Bhatt D.L., Kieth A.A., Fox M.B., Berger G.P., Black H.R., Boden W.E., et al. for the CHARISMA investigators: Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events. N Engl J Med (2006) 354
13. Nelson M.R., Liew D., Bertram M., and Vos T. Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged > or =70. BMJ 330 7503 (2005 Jun 4) 1306
14. The European Stroke Initiative Executive Committee and the EUSI Writing Committee. European stroke initiative recommendations for stroke management - update 2003. Cerebrovasc Dis 16 (2003) 311-337
15. Amarenco P., Bogousslavsky J.C., Callahan A., Goldstein L., Hennerici M., Sillesen H., et al. A placebo-controlled trial of high-dose atorvastatin in patients with recent stroke or transient ischemic attack. The Stroke Prevention with Aggressive Reduction in Cholesterol Levels (SPARCL) Study. New England Journal of Medicine 355 6 (Aug 10, 2006) 549-559
16. Schwartz G.G., Olsson A.G., Ezekowitz M., Ganz P., Oliver M.F., Waters D.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 285 13 (2001 Apr 4) 1711-1718
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 1-12
18. LaRosa J.C., Grundy S.M., Waters D.D., Shear C., Barter P., Fruchart J.C., et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 352 14 (2005 Apr 7) 1425-1435
19. Cannon C.P., Braunwald E., McCabe C.H., Rader D.J., Rouleau J.L., and Belder R. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 350 15 (2004 Apr 8) 1495-1504
20. Pedersen T.R., Faergeman O., Kastelein J.J., Olsson A.G., Tikkanen M.J., Holme I., et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 294 19 (2005 Nov 16) 2437-2445
21. European Society for Hypertension. ESH-ESC guidelines management of arterial hypertension (2007).
22. The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin converting enzyme inhibitor, Ramipril, on cardiovascular events in high risk patients. N Engl J Med 342 (2000) 145-153
23. Östergren J., Sleight P., Dagenais G., Danisa K., Bosch J., Qilong Y., et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal 25 (2004) 17-24
24. Dahlöf B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 359 (2002) 995-1003
25. International diabetes federation guidelines to treatment of diabetes
26. Gaede P., Vedel P., Larsen N., Jensen G.V., Parving H.H., and Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348 5 (2003 Jan 30) 383-393
27. Sillesen H., Madelung S., Eldrup N., and Roed M. Organising a nurse-driven PAD rehabilitation clinic within the vascular surgical department: what is required and are treatment goals reached - a prospective study?. Eur J Vasc Endovasc Surg 33 1 (2007 Jan) 26-32